Research

Hormonal

Semaglutide treatment (1 mg/week) in people with HIV and metabolic dysfunction-associated steatotic liver disease causes a significant decrease in psoas muscle volume (~9.3%) without causing a statistically significant decline in physical function (gait speed and chair rise tests).

If you are taking semaglutide for weight loss or liver health, expect to lose some muscle volume along with fat. This study suggests your physical function (like walking speed and ability to stand up) may not decline, but to be safe, incorporate resistance training into your routine to help preserve muscle mass and strength.

ModerateQualifiesMEDIUM confidence
Psoas muscle volume decreased by 9.3% (95% confidence interval [CI]: −13.4 to −5.2; P < .001) over 24 weeks... Chair rise and gait speed showed nonsignificant improvements... suggesting function was maintained despite significant loss of muscle.
Grace L. Ditzenberger et al. · Clinical Infectious Diseases · 2024

Why this rating

Single-arm pilot study with a small sample size (n=46 for muscle measures), lacking a placebo control group.

Source

Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study

Grace L. Ditzenberger et al. · Clinical Infectious Diseases · 2024

DOI 10.1093/cid/ciae384

cohort · n=51Cited 30×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →